Super-enhancers comprise dense transcription factor platforms highly enriched for active chromatin marks. A paucity of functional data led us to investigate the role of super-enhancers in the mammary gland, an organ characterized by exceptional gene regulatory dynamics during pregnancy. ChIP-seq analysis for the master regulator STAT5A, the glucocorticoid receptor, H3K27ac and MED1 identified 440 mammary-specific super-enhancers, half of which were associated with genes activated during pregnancy. We interrogated the Wap super-enhancer, generating mice carrying mutations in STAT5-binding sites within its constituent enhancers. Individually, the most distal site displayed the greatest enhancer activity. However, combinatorial mutation analysis showed that the 1,000-fold induction in gene expression during pregnancy relied on all enhancers. Disabling the binding sites of STAT5, NFIB and ELF5 in the proximal enhancer incapacitated the entire super-enhancer. Altogether, these data suggest a temporal and functional enhancer hierarchy. The identification of mammary-specific super-enhancers and the mechanistic exploration of the Wap locus provide insights into the regulation of cell-type-specific expression of hormone-sensing genes.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Hennighausen, L. & Robinson, G.W. Information networks in the mammary gland. Nat. Rev. Mol. Cell Biol. 6, 715–725 (2005).
Lydon, J.P. et al. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev. 9, 2266–2278 (1995).
Ormandy, C.J. et al. Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes Dev. 11, 167–178 (1997).
Horseman, N.D. et al. Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. EMBO J. 16, 6926–6935 (1997).
Liu, X. et al. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev. 11, 179–186 (1997).
Cui, Y. et al. Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol. Cell. Biol. 24, 8037–8047 (2004).
Zhou, J. et al. Elf5 is essential for early embryogenesis and mammary gland development during pregnancy and lactation. EMBO J. 24, 635–644 (2005).
Wakao, H., Gouilleux, F. & Groner, B. Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response. EMBO J. 13, 2182–2191 (1994).
Liu, X., Robinson, G.W., Gouilleux, F., Groner, B. & Hennighausen, L. Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue. Proc. Natl. Acad. Sci. USA 92, 8831–8835 (1995).
Yamaji, D., Kang, K., Robinson, G.W. & Hennighausen, L. Sequential activation of genetic programs in mouse mammary epithelium during pregnancy depends on STAT5A/B concentration. Nucleic Acids Res. 41, 1622–1636 (2013).
Hennighausen, L.G. & Sippel, A.E. Characterization and cloning of the mRNAs specific for the lactating mouse mammary gland. Eur. J. Biochem. 125, 131–141 (1982).
Richards, D.A., Rodgers, J.R., Supowit, S.C. & Rosen, J.M. Construction and preliminary characterization of the rat casein and α-lactalbumin cDNA clones. J. Biol. Chem. 256, 526–532 (1981).
Pittius, C.W., Sankaran, L., Topper, Y.J. & Hennighausen, L. Comparison of the regulation of the whey acidic protein gene with that of a hybrid gene containing the whey acidic protein gene promoter in transgenic mice. Mol. Endocrinol. 2, 1027–1032 (1988).
Li, S. & Rosen, J.M. Distal regulatory elements required for rat whey acidic protein gene expression in transgenic mice. J. Biol. Chem. 269, 14235–14243 (1994).
Li, S. & Rosen, J.M. Nuclear factor I and mammary gland factor (STAT5) play a critical role in regulating rat whey acidic protein gene expression in transgenic mice. Mol. Cell. Biol. 15, 2063–2070 (1995).
McKnight, R.A., Wall, R.J. & Hennighausen, L. Expression of genomic and cDNA transgenes after co-integration in transgenic mice. Transgenic Res. 4, 39–43 (1995).
Burdon, T.G., Maitland, K.A., Clark, A.J., Wallace, R. & Watson, C.J. Regulation of the sheep β-lactoglobulin gene by lactogenic hormones is mediated by a transcription factor that binds an interferon-γ activation site–related element. Mol. Endocrinol. 8, 1528–1536 (1994).
Greenberg, N.M., Reding, T.V., Duffy, T. & Rosen, J.M. A heterologous hormone response element enhances expression of rat β-casein promoter-driven chloramphenicol acetyltransferase fusion genes in the mammary gland of transgenic mice. Mol. Endocrinol. 5, 1504–1512 (1991).
Gordon, K. et al. Production of human tissue plasminogen activator in transgenic mouse milk. 1987. Biotechnology 24, 425–428 (1992).
Shlyueva, D., Stampfel, G. & Stark, A. Transcriptional enhancers: from properties to genome-wide predictions. Nat. Rev. Genet. 15, 272–286 (2014).
Ong, C.T. & Corces, V.G. Enhancer function: new insights into the regulation of tissue-specific gene expression. Nat. Rev. Genet. 12, 283–293 (2011).
Ong, C.T. & Corces, V.G. Enhancers: emerging roles in cell fate specification. EMBO Rep. 13, 423–430 (2012).
Natoli, G. & Andrau, J.C. Noncoding transcription at enhancers: general principles and functional models. Annu. Rev. Genet. 46, 1–19 (2012).
Heinz, S., Romanoski, C.E., Benner, C. & Glass, C.K. The selection and function of cell type–specific enhancers. Nat. Rev. Mol. Cell Biol. 16, 144–154 (2015).
Pott, S. & Lieb, J.D. What are super-enhancers? Nat. Genet. 47, 8–12 (2015).
Adam, R.C. et al. Pioneer factors govern super-enhancer dynamics in stem cell plasticity and lineage choice. Nature 521, 366–370 (2015).
Brown, J.D. et al. NF-κB directs dynamic super enhancer formation in inflammation and atherogenesis. Mol. Cell 56, 219–231 (2014).
Chapuy, B. et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell 24, 777–790 (2013).
Chipumuro, E. et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell 159, 1126–1139 (2014).
Fang, Z. et al. Transcription factor co-occupied regions in the murine genome constitute T-helper-cell subtype-specific enhancers. Eur. J. Immunol. 45, 3150–3157 (2015).
Gosselin, D. et al. Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. Cell 159, 1327–1340 (2014).
Hnisz, D. et al. Super-enhancers in the control of cell identity and disease. Cell 155, 934–947 (2013).
Hnisz, D. et al. Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers. Mol. Cell 58, 362–370 (2015).
Huang, J. et al. Dynamic control of enhancer repertoires drives lineage and stage-specific transcription during hematopoiesis. Dev. Cell 36, 9–23 (2016).
Li, Y. et al. CRISPR reveals a distal super-enhancer required for Sox2 expression in mouse embryonic stem cells. PLoS One 9, e114485 (2014).
Liu, C.F. & Lefebvre, V. The transcription factors SOX9 and SOX5/SOX6 cooperate genome-wide through super-enhancers to drive chondrogenesis. Nucleic Acids Res. 43, 8183–8203 (2015).
Lovén, J. et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153, 320–334 (2013).
Mansour, M.R. et al. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science 346, 1373–1377 (2014).
Ohba, S., He, X., Hojo, H. & McMahon, A.P. Distinct transcriptional programs underlie Sox9 regulation of the mammalian chondrocyte. Cell Rep. 12, 229–243 (2015).
Parker, S.C. et al. Chromatin stretch enhancer states drive cell-specific gene regulation and harbor human disease risk variants. Proc. Natl. Acad. Sci. USA 110, 17921–17926 (2013).
Pelish, H.E. et al. Mediator kinase inhibition further activates super-enhancer-associated genes in AML. Nature 526, 273–276 (2015).
Pinz, S., Unser, S. & Rascle, A. Signal transducer and activator of transcription STAT5 is recruited to c-Myc super-enhancer. BMC Mol. Biol. 17, 10 (2016).
Siersbæk, R. et al. Transcription factor cooperativity in early adipogenic hotspots and super-enhancers. Cell Rep. 7, 1443–1455 (2014).
Thakurela, S., Sahu, S.K., Garding, A. & Tiwari, V.K. Dynamics and function of distal regulatory elements during neurogenesis and neuroplasticity. Genome Res. 25, 1309–1324 (2015).
Vahedi, G. et al. Super-enhancers delineate disease-associated regulatory nodes in T cells. Nature 520, 558–562 (2015).
Whyte, W.A. et al. Master transcription factors and Mediator establish super-enhancers at key cell identity genes. Cell 153, 307–319 (2013).
Hennighausen, L.G. & Sippel, A.E. Mouse whey acidic protein is a novel member of the family of 'four-disulfide core' proteins. Nucleic Acids Res. 10, 2677–2684 (1982).
Burdon, T., Sankaran, L., Wall, R.J., Spencer, M. & Hennighausen, L. Expression of a whey acidic protein transgene during mammary development. Evidence for different mechanisms of regulation during pregnancy and lactation. J. Biol. Chem. 266, 6909–6914 (1991).
Siersbæk, R. et al. Extensive chromatin remodelling and establishment of transcription factor 'hotspots' during early adipogenesis. EMBO J. 30, 1459–1472 (2011).
Robinson, G.W. et al. Coregulation of genetic programs by the transcription factors NFIB and STAT5. Mol. Endocrinol. 28, 758–767 (2014).
Bayna, E.M. & Rosen, J.M. Tissue-specific, high level expression of the rat whey acidic protein gene in transgenic mice. Nucleic Acids Res. 18, 2977–2985 (1990).
Miyoshi, K. et al. Signal transducer and activator of transcription (Stat) 5 controls the proliferation and differentiation of mammary alveolar epithelium. J. Cell Biol. 155, 531–542 (2001).
Li, S. & Rosen, J.M. Glucocorticoid regulation of rat whey acidic protein gene expression involves hormone-induced alterations of chromatin structure in the distal promoter region. Mol. Endocrinol. 8, 1328–1335 (1994).
McKnight, R.A. et al. An Ets site in the whey acidic protein gene promoter mediates transcriptional activation in the mammary gland of pregnant mice but is dispensable during lactation. Mol. Endocrinol. 9, 717–724 (1995).
McKnight, R.A., Spencer, M., Wall, R.J. & Hennighausen, L. Severe position effects imposed on a 1 kb mouse whey acidic protein gene promoter are overcome by heterologous matrix attachment regions. Mol. Reprod. Dev. 44, 179–184 (1996).
Witte, S., O'Shea, J.J. & Vahedi, G. Super-enhancers: asset management in immune cell genomes. Trends Immunol. 36, 519–526 (2015).
González, A.J., Setty, M. & Leslie, C.S. Early enhancer establishment and regulatory locus complexity shape transcriptional programs in hematopoietic differentiation. Nat. Genet. 47, 1249–1259 (2015).
Zhou, H. et al. Epstein–Barr virus oncoprotein super-enhancers control B cell growth. Cell Host Microbe 17, 205–216 (2015).
Vahedi, G. et al. STATs shape the active enhancer landscape of T cell populations. Cell 151, 981–993 (2012).
Yang, X.P. et al. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat. Immunol. 12, 247–254 (2011).
Kang, K., Yamaji, D., Yoo, K.H., Robinson, G.W. & Hennighausen, L. Mammary-specific gene activation is defined by progressive recruitment of STAT5 during pregnancy and the establishment of H3K4me3 marks. Mol. Cell. Biol. 34, 464–473 (2014).
Li, P., Spolski, R., Liao, W. & Leonard, W.J. Complex interactions of transcription factors in mediating cytokine biology in T cells. Immunol. Rev. 261, 141–156 (2014).
Yao, Z. et al. Stat5a/b are essential for normal lymphoid development and differentiation. Proc. Natl. Acad. Sci. USA 103, 1000–1005 (2006).
Yao, Z. et al. Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood 109, 4368–4375 (2007).
Laurence, A. et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26, 371–381 (2007).
Wei, L., Laurence, A., Elias, K.M. & O'Shea, J.J. IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J. Biol. Chem. 282, 34605–34610 (2007).
Metser, G. et al. An autoregulatory enhancer controls mammary-specific STAT5 functions. Nucleic Acids Res. 44, 1052–1063 (2016).
Bolger, A.M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114–2120 (2014).
Langmead, B., Trapnell, C., Pop, M. & Salzberg, S.L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).
Ramírez, F., Dündar, F., Diehl, S., Grüning, B.A. & Manke, T. deepTools: a flexible platform for exploring deep-sequencing data. Nucleic Acids Res. 42, W187–W191 (2014).
Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576–589 (2010).
Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).
Neph, S. et al. BEDOPS: high-performance genomic feature operations. Bioinformatics 28, 1919–1920 (2012).
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
Huber, W. et al. Orchestrating high-throughput genomic analysis with Bioconductor. Nat. Methods 12, 115–121 (2015).
Liao, Y., Smyth, G.K. & Shi, W. The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. Nucleic Acids Res. 41, e108 (2013).
Love, M.I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
Wikham, H. Ggplot2: Elegant Graphics for Data Analysis (2009).
We thank H. Smith from the NIDDK genomics core for never-ending help with next-generation sequencing and C. Liu from the NHLBI transgenic core for generating the CRISPR/Cas9-based mouse mutants. M.W. is a graduate student of the Individual Graduate Partnership Program (GPP) between NIH/NIDDK and the Medical University of Innsbruck. This work was performed in partial fulfillment of the graduation requirements for M.W. We thank K. Kang and S. Oh for discussions in the early stage of this project and Z. Trajanoski for advising M.W. during her graduate studies. This research was funded by the IPR of the NIDDK/NIH.
The authors declare no competing financial interests.
Integrated supplementary information
Supplementary Figure 1 Representative scatterplots validating the reproducibility of ChIP-seq replicates.
(a) Reproducibility of STAT5A ChIP-seq peaks at L1. r is Spearman’s correlation coefficient. (b) Reproducibility of H3K27ac ChIP-seq peaks at L1. (c) Reproducibility of MED1 ChIP-seq peaks at L1. (d) Reproducibility of NFIB ChIP-seq peaks at L1. (e) Reproducibility of ELF5 ChIP-seq peaks at L1. (f) Reproducibility of STAT5A ChIP-seq peaks at p13.
ChIP-seq peak calling was conducted for two STAT5A replicates. Of a total of 15,790 verified peaks, 10,953 coincided with H3K27ac marks (±500 bp). 549 of these peaks coincided with known promoter regions and 10,404 were located in non-promoter regions. 5,503 of these coincided with a GAS motif (TTCNNNGAA) (±250 bp). The non-promoter STAT5 peaks served as the basis for the super-enhancer analysis calculation applying the ROSE algorithm. As the size of mammary-specific super-enhancers might be different from that of super-enhancers identified in embryonic stem cells, the analysis was carried out using three stitched sizes: 12.5 kb, 25 kb and 35 kb. To obtain only mammary-specific super-enhancers, each stitched size was used as a parameter for the calculations based on STAT5A peaks and H3K27ac, GR and MED1. The basic workflow for the analysis was applied for the three stitching sizes. The first step comprised the application of the ROSE algorithm based on STAT5A peaks: (i) a stitching size of 12.5 kb for H3K27ac returned 504 super-enhancers, for GR returned 592 super-enhancers and for MED1 returned 347 super-enhancers; (ii) the stitching size of 25 kb resulted in 392 super-enhancers for H3K27ac, 359 super-enhancers for GR and 191 super-enhancers for MED1; and (iii) the third applied size of 35 kb specified 428 super-enhancers for H3K27ac, 424 super-enhancers for GR and 199 super-enhancers for MED1. Subsequently, these super-enhancers were overlapped, and only super-enhancers identified and reproduced for at least two factors (gray) were considered for following analysis. With regard to the three stitching sizes, this criterion was satisfied by 405 super-enhancers for 12.5 kb, 272 super-enhancers for 25 kb and 311 super-enhancers for 35 kb. Mammary-specific super-enhancers were identified from the subtraction of STAT5 super-enhancers shared with T cells and liver (12.5 kb), if at least 30% of the mammary super-enhancer overlapped with the T cell and liver ones. 347 mammary-specific super-enhancers were identified in the category with 12.5 kb, 233 mammary-specific enhancers were identified for the category with 25 kb and 270 mammary-specific super-enhancers were identified using a stitched size of 35 kb. These mammary-specific super-enhancers were annotated taking into account the two nearest genes, choosing the one with the higher FPKM value based on expression data obtained at day 1 of lactation. In the final step, nested super-enhancers, which had been annotated to the same gene, were removed, and a total of 440 high-confidence mammary-specific super-enhancers were obtained.
(a) The Glycam1 locus is shown as an example of a mammary-specific super-enhancer. STAT5 binding and H3K27ac marks exist only in mammary tissue but not in T cells or liver. (b) The Aldoc locus is shown as an example of a highly expressed mammary gene with a lone enhancer.
Supplementary Figure 4 Transcription factor binding profile within a mammary-specific super-enhancer.
The Olah super-enhancer consists of three constituent enhancers (asterisk) that feature colocalization of STAT5A, GR, NFIB, ELF5, MED1 and H3K27ac.
Established super-enhancers (n = 22; mean of ~205 FPKM) show higher gene expression at day 13 of pregnancy than progressive super-enhancers from groups II and III (n = 386; mean of ~46 FPKM). Median, middle bar inside the box; IQR, 50% of the data; whiskers, 1.5 times the IQR.
Supplementary Figure 6 Transcription factor binding at a putative super-enhancer controlling the Csn locus.
(a) Transcription factor binding is shown at day 13 of pregnancy and day 1 of lactation. Transcription factor binding and H3K27ac marks are similar at these two developmental stages. (b) STAT5A binding and H3K27ac marks are shown at days 13, 14 and 16 of pregnancy and day 1 of lactation. STAT5A binding and H3K27ac marks are similar across the developmental stages.
Supplementary Figure 7 Alveolar development at days 13, 14 and 16 of pregnancy and day 1 of lactation.
(a) Sections of mammary tissue stained with hematoxylin and eosin at days 13, 14 and 16 of pregnancy and day 1 of lactation with low magnification (400×). The arrow indicates alveoli. At days 13 and 14 of pregnancy, mammary glands were sparsely filled with undeveloped alveoli. The degree of alveolar occupancy was similar at day 16 of pregnancy. At day 1 of lactation, mammary glands were filled with fully differentiated alveoli containing milk (asterisk). (b) Sections of mammary tissue stained with hematoxylin and eosin at days 13, 14 and 16 of pregnancy and day 1 of lactation with high magnification (800×).
Supplementary Figure 8 Scatterplots showing the relationship between mammary epithelial cell and mammary tissue ChIP-seq.
(a) The scatterplot depicts the correlation between mammary tissue and MECs at day 13 of pregnancy. r is Spearman’s correlation coefficient. (b) The scatterplot depicts the correlation between mammary tissue and MECs at day 1 of lactation.
Supplementary Figure 9 Characterization of mutant mice generated by CRISPR/Cas9, TALEN and homologous recombination to introduce point mutations.
ΔE1a carries an 11-bp deletion spanning the GAS motif in E1 (0.7 kb upstream of the TSS), and ΔE1b has a 27-bp deletion spanning the GAS motif and juxtaposed NFIB motif in E1. ΔE1c carries point mutations in the GAS, NFIB and ELF5 motifs in E1. The GAS motif is in red, the NFIB motif is in blue and the ELF5 motif is in green. Point mutations are underlined. ΔE2 has a 26-bp deletion spanning the GAS motif in E2 (1.4 kb upstream of the TSS), and ΔE3 has an 11-bp deletion spanning the GAS motif in E3 (5.6 kb upstream of the TSS). ΔE1a/ΔE2 has a 16-bp deletion spanning the GAS motif in E1 and a 6-bp deletion spanning the GAS motif in E2. ΔE2/ΔE3 has a 9-bp deletion spanning the GAS motif in E2 and an 11-bp deletion spanning the GAS motif in E3. ΔE1a/ΔE2/ΔE3 carries deletions in all three GAS sites.
(a) Binding of STAT5, NFIB and ELF5 does not coincide with the GAS motif at E1, whereas binding of NFIB and ELF5 colocalizes with STAT5 binding at E2. (b) ELF5 binding remains in ΔE1a, whereas ELF5 binding is absent in ΔE2, indicating that ELF5 binding is dependent on STAT5A at the E2 site.
Supplementary Figure 11 Transcription factor binding at the Wap super-enhancer in ΔE1b and ΔE1c mutant mice.
Binding of STAT5A and NFIB was reduced at the E1 site in ΔE1b mutant mice. Binding of STAT5A, NFIB and ELF5 was completely absent at the E1 site in ΔE1c mutant mice. The Lao1 locus is shown as a ChIP-seq control.
(a) STAT5A binding and H3K27ac marks are enriched in a putative regulatory region of the Nfib locus. (b) STAT5A binding and H3K27ac marks are enriched in a putative regulatory region of the Elf5 locus.
Supplementary Figures 1–12 and Supplementary Tables 4 and 5. (PDF 1827 kb)
Genes associated with mammary-specific super-enhancers. (XLSX 1702 kb)
Summary table for current super-enhancer studies. (XLSX 12 kb)
ChIP-seq mapping quality. (XLSX 20 kb)
About this article
Cite this article
Shin, H., Willi, M., Yoo, K. et al. Hierarchy within the mammary STAT5-driven Wap super-enhancer. Nat Genet 48, 904–911 (2016). https://doi.org/10.1038/ng.3606
Dynamic CpG methylation delineates subregions within super-enhancers selectively decommissioned at the exit from naive pluripotency
Nature Communications (2020)
Experimental & Molecular Medicine (2020)
Reciprocal fine-tuning of progesterone and prolactin-regulated gene expression in breast cancer cells
Molecular and Cellular Endocrinology (2020)
PLOS Genetics (2020)
Frontiers in Cell and Developmental Biology (2020)